GLP-1 receptor agonist use and overall survival among women with type 2 diabetes and breast cancer: a retrospective cohort study
The Oncologist · 2026
DOI: 10.1093/oncolo/oyag268 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Oncologist, 2026. Verfasst von Rebecca A Nelson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computational and Quantitative Medicine, Beckman Research Institute, City of Hope, Duarte, CA, 91010, United States. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Breast Neoplasms, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ko Family Foundation, Allen and Lee Hwa Chao Research Fund, and Tseng Visiting Scholar Fellowship.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Diabetes and obesity are associated with worse prognosis in women with breast cancer. However, the impact of glucagon-like peptide-1 receptor agonists (GLP-1RA) on survival following breast cancer diagnosis remains unclear.
Methods
We conducted a single institution, propensity-score matched, retrospective, 2-year landmark study of women with type 2 diabetes (T2D) diagnosed with breast cancer at City of Hope (2009-2025). Patients were categorized based on post-diagnosis exposure to GLP-1RA. Patients were compared across exposure groups using t-tests for continuous variables, chi-square tests for categorical variables, multivariable Cox proportional hazards models for overall mortality risk, and Kaplan-Meier plots for survival time.
Results
In 226 matched pairs, there were 47 deaths (30 in unexposed patients and 17 in exposed patients). GLP-1RA exposure was associated with a significantly lower risk of overall mortality (HR = 0.51, 95% CI 0.28-0.93, P = .03) on multivariable analysis. A sensitivity analysis in stage I-III patients yielded similar results (HR = 0.45, 95% CI 0.23-0.85, P = .01). Kaplan-Meier survival analysis also showed an association between increased overall survival and GLP-1RA exposure (log-rank P = .02).
Conclusions
In this retrospective cohort of women with T2D and breast cancer, GLP-1RA use after diagnosis was associated with improved overall survival in T2D. These findings reflect all-cause mortality and do not distinguish between cancer-specific and non-cancer causes of death and should therefore be interpreted accordingly.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Computational and Quantitative Medicine, Beckman Research Institute, City of Hope, Duarte, CA, 91010, United States.
- Department of Internal Medicine, National Taiwan University Hospital, Taipei City, 100229, Taiwan.
- Department of Diabetes, Endocrinology, and Metabolism, City of Hope National Medical Center, Duarte, CA, 91010, United States.
- Arthur Riggs Diabetes & Metabolism Research Institute, Beckman Research Institute, City of Hope, Duarte, CA, 91010, United States.
- Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, CA, 91010, United States.
ORCID-Profile: Rebecca A Nelson, Ying-Chuen Lai, Sung H Kil, Joanne Mortimer, Ping H Wang
Förderung
- Ko Family Foundation, Allen and Lee Hwa Chao Research Fund, and Tseng Visiting Scholar Fellowship
Zitieren
APA
Nelson, R. A., Lai, Y. C., Kil, S. H., Lee, H. S., Mortimer, J., & Wang, P. H. (2026). GLP-1 receptor agonist use and overall survival among women with type 2 diabetes and breast cancer: a retrospective cohort study. The Oncologist. https://doi.org/10.1093/oncolo/oyag268
Vancouver
Nelson RA, Lai YC, Kil SH, Lee HS, Mortimer J, Wang PH. GLP-1 receptor agonist use and overall survival among women with type 2 diabetes and breast cancer: a retrospective cohort study. The Oncologist. 2026. doi:10.1093/oncolo/oyag268
BibTeX
@article{Nelson2026,
author = {Nelson, Rebecca A and Lai, Ying-Chuen and Kil, Sung H and Lee, Hayley S and Mortimer, Joanne and Wang, Ping H},
title = {GLP-1 receptor agonist use and overall survival among women with type 2 diabetes and breast cancer: a retrospective cohort study},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag268}
}
EUVIMED